Dr. Antonarakis describes optimal populations for genetic testing in prostate cancer

Emmanuel S. Antonarakis, MD, explains the optimal patient populations who should receive genetic testing in both the localized and metastatic prostate cancer settings. Antonarakis is discussing genetic testing in patients with prostate cancer during the CME program at the 2022 LUGPA Annual Meeting. He is associate director for Translational Research at the University of Minnesota Medical School Masonic Cancer Center, as well as the Clark Endowed Professor of Medicine and director of Genitourinary Oncology in the Department of Medicine’s Division of Hematology, Oncology, and Transplantation.